Exicure (NASDAQ:XCUR) Releases Earnings Results, Beats Estimates By $18.14 EPS

Exicure (NASDAQ:XCUR) posted its quarterly earnings data on Wednesday. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.14, FiscalAI reports.

Exicure Price Performance

Shares of NASDAQ:XCUR traded up $0.02 during midday trading on Wednesday, hitting $4.49. The company had a trading volume of 16,841 shares, compared to its average volume of 33,996. Exicure has a 12-month low of $3.10 and a 12-month high of $14.73. The company has a fifty day moving average of $4.44 and a two-hundred day moving average of $4.66. The company has a market cap of $28.60 million, a price-to-earnings ratio of -1.21 and a beta of 4.13.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Exicure to a “hold” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Exicure currently has a consensus rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.